DR. REDDY’S LABORATORIES LIMITED.
Dr. Anji Reddy founded the Dr. Reddy’s Laboratories Limited in the year 1984, in Hyderabad. Reddy who is from an agricultural family, had much interest in chemical engineering and In the year 1969, he got a doctorate. In his early ages, he worked as a scientist in Indian Drugs and Pharmaceuticals Limited, and he was part of many establishments such as Unilods Limited and Standard Organics Limited between 1979 and 1984, after which he founded DRL.
DRL became a public limited company in the year 1986, and pharmaceutical drugs export also commenced in the same year. DRL got its USFDA approval in the year 1987.In 1988, it acquired Benzex Laboratories Pvt. Ltd, a bulk drugs manufacturing company, to raise its bulk drugs business, which evolved India into a self reliant industry in bulk drugs. It started its global expansion plans in the early 1990s, by entering into Russia, Far East and Europe.
In 1993, DRF, Dr. Reddy’s Research Foundation was formed, to discover new drugs rather than doing reverse engineering of the drugs discovered by others. In 1997, it licensed out an anti diabetes molecule. Gradually it became a vertically integrated global pharmaceutical company.
In 2000, DRL acquired Cheminor Drugs Limited. In 2001, DRL emerged as the first Asian pharmaceutical company to be listed in the NYSE. In 2002, it acquired BMS Laboratories Limited, UK and also acquired Meridian healthcare, UK. By 2005, it acquired Trigenesis, USA and Roche’s API division, Mexico also.
In 2006, DRL was into 5 segments:
- Formulation
- Drug Discovery
- Generics
- Active pharmaceutical ingredients and intermediates
- Critical Care and Biotechnology
It operated in more than 100 countries with 950 scientists involved in drug discovery program. It also focused on social initiatives with its NAANDI foundation, Center for Social Initiative and Management and Dr. Reddy’s Foundation. It had very well recognized CSR initiatives too.